It targets GLP-1 receptors , GIP receptors, and glucagon receptors all at once, creating a cascade of metabolic changes that affect appetite from multiple angles
Effects of menopause and high-intensity training on insulin sensitivity and muscle metabolism
It has shown promising results in clinical trials, helping individuals achieve significant weight loss when combined with a healthy diet and exercise regimen
Safety and discontinuation rates are comparable to other GLP-1 drugs
Court Decision Prevents Compounders from Producing Knockoffs of Novo Nordisks Semaglutide Grand View Research, UK GLP-1 Receptor Agonist Market Harvard University, GLP-1 Diabetes and Weight Loss Drug Side Effects: Ozempic Face and More Diabetes.org, How Many People in the UK Have Diabetes? CDC, National Diabetes Statistics Report WHO, Obesity and Overweight Health.com, Think GLP-1s Guarantee Weight Loss
GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
